PT  - JOURNAL ARTICLE
AU  - Christensen, Robert D
AU  - Henry, Erick
AU  - Baer, Vickie L
AU  - Hoang, Nhan
AU  - Snow, Gregory L
AU  - Rigby, Gorgi
AU  - Burnett, Jill
AU  - Wiedmeier, Susan E
AU  - Faix, Roger G
AU  - Eggert, Larry D
TI  - A Low-Sodium Solution for Airway Care: Results of a Multicenter Trial
DP  - 2010 Dec 01
TA  - Respiratory Care
PG  - 1680--1685
VI  - 55
IP  - 12
4099  - http://rc.rcjournal.com/content/55/12/1680.short
4100  - http://rc.rcjournal.com/content/55/12/1680.full
AB  - BACKGROUND: Normal saline is sometimes instilled into the endotracheal tube preparatory to airway suctioning, to assist in removing thick secretions. However, saline can damage the antimicrobial properties of airway secretions. We previously described a low-sodium physiologically based solution for airway care and reported a small (n = 60) randomized trial in neonates, which showed trends toward less ventilator-associated pneumonia (VAP) and less chronic lung disease with the new solution. We now report a multicenter trial of that solution. METHODS: We conducted a before-and-after study with a parallel control group, in 4 level-3 neonatal intensive care units (NICUs). During year 1, all 4 NICUs used saline for airway care. During year 2, one NICU used the test solution exclusively while the other NICUs used saline exclusively. The 2 study outcomes were VAP (cases/1,000 ventilator days) and chronic lung disease, defined 3 ways: supplemental oxygen at 28 days; supplemental oxygen at 36 weeks gestation; and supplemental oxygen on hospital discharge. RESULTS: During the study period 1,116 neonates had endotracheal intubation for respiratory management. Of those, 1,029 received the standard saline for airway suctioning, and the 87 in NICU 4 received the test solution. NICU 4 had a decrease in VAP rate, from 4.2 VAPs/1,000 ventilator days with saline, to 1.6 VAPs/1,000 ventilator days with the test solution (P = .04), and also had the lowest prevalence of chronic lung disease (P < .001 for each definition). CONCLUSIONS: The test solution significantly reduced the VAP and chronic lung disease rates.